Search Results - "Laporte, Montas"

Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil by Laporte, Montas, Metelus, Sherly, Ali, Moazzam, Bahamondes, Luis

“…Objective To compare the sociodemographic characteristics of users of the copper intrauterine device (Cu‐IUD) and the levonorgestrel intrauterine system…”
Get full text

Barriers to accessing post-pregnancy contraception in Brazil: The impact of COVID-19 by Juliato, Cássia R.T., Laporte, Montas, Surita, Fernanda, Bahamondes, Luis

“…The aim of our article is to discuss barriers associated with post-pregnancy contraception in Brazil during the SARS-CoV-2 (COVID-19) pandemic. Socioeconomic…”
Get full text

Reasons for satisfaction with the use of the 52‐mg levonorgestrel intrauterine system by Laporte, Montas, Charles, Charles M., Metelus, Sherly, Souza, Rafael B., Peloggia, Alessandra, Bahamondes, Luis

“…Objectives To assess the reasons to use, reasons they liked, satisfaction with, and possibilities of recommendation to other women of the levonorgestrel 52‐mg…”
Get full text

Uptake, discontinuation, and continuation rate of long-acting contraceptive methods when offered at no cost in Campinas, Brazil by Laporte, Montas, Marcelino, Ana C., Pereira, Paula da Cunha, Espejo-Arce, Ximena, Juliato, Cassia T., Bahamondes, Luis

“…This study aimed to compare the uptake, reasons for discontinuation, continuation, and satisfaction of long-acting contraceptive methods (LARC) when offered at…”
Get full text

Postplacental placement of intrauterine devices: A randomized clinical trial by Laporte, Montas, Marangoni, Marcos, Surita, Fernanda, Juliato, Cassia T., Miadaira, Mariana, Bahamondes, Luis

“…To compare the expulsion rate of the TCu380A intrauterine device (IUD) or levonorgestrel (LNG) 52 mg intrauterine system (IUS) up to 90 days after…”
Get full text

Single‐visit long‐acting reversible contraception provision and pregnancy rates within 3 months by Manhiça, Suzana I., Bahamondes, Luis, Laporte, Montas, Anjos, Fabiana, Viscola, Marco, Garcia, Elaine, Paiva, Lucia C.

“…Objectives To assess the occurrence of pregnancy in a cohort of women who received a copper intrauterine device (IUD), hormonal IUDs or an etonogestrel (ENG)…”
Get full text

Effectiveness and continuation rates of the etonogestrel‐subdermal contraceptive implant versus short‐acting contraceptive methods offered at no cost in Campinas, Brazil by Laporte, Montas, Marcelino, Ana C., Cunha Pereira, Paula, Espejo‐Arce, Ximena, Juliato, Cassia T., Bahamondes, Luis

“…Objectives To compare the efficacy, reasons for discontinuation and continuation rates of the etonogestrel (ENG)‐subdermal contraceptive implant when offered…”
Get full text

Evaluation of clinical performance when intrauterine devices are inserted by different categories of healthcare professional by Laporte, Montas, Becerra, Alejandra, Castro, Lester, Veiga, Nelio, Espejo‐Arce, Ximena, Bahamondes, Luis

“…Objective We evaluated clinical performance when the TCu380A intrauterine device (IUD) and the levonorgestrel (LNG) 52‐mg intrauterine system (IUS) were…”
Get full text

One-year follow up on post-placental IUD insertion: A randomized clinical trial by Marangoni, Jr, Marcos, Laporte, Montas, Surita, Fernanda, Kraft, Maria B, Bahamondes, Luis, Juliato, Cássia R T

“…Our objectives were to compare the 1-year follow-up clinical performance of the TCu380A intrauterine device (TCu380A-IUD) and levonorgestrel (LNG) 52-mg…”
Get more information

Perspectives of health care providers regarding the levonorgestrel-releasing intrauterine system by Laporte, Montas, Peloggia, Alessandra, Marcelino, Ana C., de Carvalho, Larissa S., Bahamondes, Luis

“…The aims of the study were to assess the number of insertions per month of the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS) and gauge the…”
Get full text

Women's perspectives on impact on the post menopause of use of the 52 mg levonorgestrel intrauterine device during the menopausal transition by Versailles, Jacques B. E., Metelus, Sherly, Peloggia, Alessandra, Laporte, Montas, Bahamondes, Luis, Juliato, Cassia

“…The 52 mg hormonal-IUD who were at menopausal transition reported worries that the use of the IUD can affect menopausal symptoms. It is important that health…”
Get full text

Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method by Laporte, Montas, Charles, Charles M., Metelus, Sherly, Peloggia, Alessandra, Paez, Gabriela de O., Juliato, Cassia T., Bahamondes, Luis

“…Objective To assess the reasons provided by women for choosing the use of the 52 mg levonorgestrel intrauterine system (LNG‐IUS) as a contraceptive method…”
Get full text